Dr. Davids on Checkpoint Blockade Inhibition in Hematologic Malignancies After Stem Cell Transplant – OncLive
OncLive |
Dr. Davids on Checkpoint Blockade Inhibition in Hematologic Malignancies After Stem Cell Transplant
OncLive Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic … Study Explores Use of Checkpoint Inhibitors After Relapse From Donor Stem Cell Transplant for Hematologic Cancers Low-dose treatment with Il2 across studies shows benefits in chronic graft-versus host |
